AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion
2,79 EUR
+1,09 %+0,03
14. Nov, 07:26:07 Uhr,
L&S Exchange
Kommentare 1.138
Hopper58,
03.07.2024 8:35 Uhr
0
Ich denke, Abcellera spielte eine Rolle bei der Entdeckung dieser Medikamente. Siehe Vertrag zwischen beiden Unternehmen im Jahr 2022:
Buy Rating on Regeneron: Promising Obesity Treatment Prospects Amid Phase 2 Trials
Carrie Williams
Jun 26, 2024, 09:37 AM
David Risinger has given his Buy rating due to a combination of factors surrounding Regeneron’s innovative approach in the obesity treatment space. The recent Phase 1 study of trevogrumab and garetosmab, presented at a prestigious medical conference, indicated potential improvements in body composition and a slight decrease in body weight among participants. Although there were some safety concerns with muscle spasms reported, Regeneron has strategically designed a Phase 2 trial to mitigate side effects, particularly focusing on the use of garetosmab. The anticipation of significant Phase 2 outcomes, including the effects on body weight, fat, and muscle mass, set to be released in the second half of 2025, provides a promising outlook for the stock’s future performance.
Furthermore, Risinger’s optimistic stance is reinforced by the observed increases in muscle mass and reductions in fat mass from the multiple dose data of the study. These positive trends, along with the meticulous study design that seeks to enhance efficacy while minimizing adverse effects, contribute to the favorable evaluation of Regeneron’s shares. The company’s cautious approach in not including any obesity revenues in its financial model due to the early stage of the program suggests a conservative and potentially upside-biased financial projection. This prudence, paired with the potential for a breakthrough in a challenging therapeutic area like obesity, underscores the rationale behind the Buy rating for Regeneron.
According to TipRanks, Risinger is a 5-star analyst with an average return of 12.5% and a 59.24% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Johnson & Johnson, and Sanofi. https://www.tipranks.com/news/blurbs/buy-rating-on-regeneron-promising-obesity-treatment-prospects-amid-phase-2-trials?mod=mw_quote_news
Hopper58,
03.07.2024 8:38 Uhr
0
TD Cowen Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
Jason Carr
Jun 28, 2024, 01:58 PM
In a report released today, Steven Mah from TD Cowen maintained a Buy rating on AbCellera Biologics (ABCL – Research Report). The company’s shares closed yesterday at $2.88.
According to TipRanks, Mah is an analyst with an average return of -17.5% and a 22.44% success rate. Mah covers the Healthcare sector, focusing on stocks such as Evotec AG, Twist Bioscience, and AbSci.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AbCellera Biologics with a $12.60 average price target. https://www.tipranks.com/news/blurbs/td-cowen-reaffirms-their-buy-rating-on-abcellera-biologics-abcl?mod=mw_quote_news
Arras,
07.06.2024 18:57 Uhr
0
Abcellera biologics Soll sich 👉👌 drecksladen seit Jahren nur Berg ab Um uns kleinen zu b u msen
Arras,
24.05.2024 15:32 Uhr
0
Herzlichen Glückwunsch an unseren Partner Abdera Therapeutics zur FDA-Zulassung für seinen IND-Antrag für ABD-147, ein antikörperbasiertes Präzisions-Strahlentherapeutikum gegen kleinzelligen Lungenkrebs und großzelliges neuroendokrines Karzinom. https://lnkd.in/esxvb9dQ
Da wird eh nichts passieren ist nur fakenews
Chris84,
23.05.2024 21:22 Uhr
1
Herzlichen Glückwunsch an unseren Partner Abdera Therapeutics zur FDA-Zulassung für seinen IND-Antrag für ABD-147, ein antikörperbasiertes Präzisions-Strahlentherapeutikum gegen kleinzelligen Lungenkrebs und großzelliges neuroendokrines Karzinom. https://lnkd.in/esxvb9dQ
Mehr zu diesem Wert
|
Thema | ||
---|---|---|---|
1 | AbCellera Biologics Hauptdiskussion | ||
2 | Daytrader ABCellera📈 |
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | Trading- und Aktien-Chat | ||
2 | für alle, die es ehrlich meinen beim Traden. | ||
3 | Super Micro Computer Hauptdiskussion | ±0,00 % | |
4 | SMA SOLAR Hauptdiskussion | -0,62 % | |
5 | BAYER Hauptdiskussion | -0,15 % | |
6 | GEELY Hauptdiskussion | +0,71 % | |
7 | New World (alt Graph Blockchaine) | ±0,00 % | |
8 | Wonderfi Technologies Inc Hauptforum | +1,01 % | |
9 | Zeta Global Holdings | +0,32 % | |
10 | GAMESTOP Hauptdiskussion | +1,16 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | Super Micro Computer Hauptdiskussion | ±0,00 % | |
2 | SMA SOLAR Hauptdiskussion | -0,62 % | |
3 | BAYER Hauptdiskussion | -0,15 % | |
4 | New World (alt Graph Blockchaine) | ±0,00 % | |
5 | GEELY Hauptdiskussion | +0,71 % | |
6 | Wonderfi Technologies Inc Hauptforum | +1,01 % | |
7 | Zeta Global Holdings | +0,32 % | |
8 | GAMESTOP Hauptdiskussion | +1,16 % | |
9 | DEUTSCHE TELEKOM Hauptdiskussion | +0,56 % | |
10 | VW Hauptdiskussion | -0,10 % | Alle Diskussionen |